Gastroenterology
Volume 124, Issue 4 , Pages 889-893 , April 2003

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

Presented in part at the 102nd Annual Meeting of the American Gastroenterological Association, May 20-23, 2001, Atlanta, Georgia (Gastroenterology 2001;120:A447).

Received 2 October 2002 ,Accepted 20 December 2002.

References 

  1. Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:459–477
  2. Weisner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79:200–206
  3. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94:1643–1649
  4. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404–1408
  5. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41:522–525
  6. Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997;92:1285–1288
  7. Leidenius MH, Farkkila MA, Karkkainen P, Taskinen EI. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol. 1997;32:706–711
  8. Brentnall TA, Haggitt RC, Ravbinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1996;110:331–338
  9. Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis—a risk factor for the development of dysplasia and DNA aneuploidy?. Gastroenterology. 1992;102:1877–1880
  10. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol. 1993;88:1174–1178
  11. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastorenterol. 1996;91:44–48
  12. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis. Cancer. 1998;82:822–826
  13. Gurbuz AK, Giardello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum. 1995;38:37–141
  14. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996;110:432–440
  15. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 1998;31:111–118
  16. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Can Res. 1999;18:259–266
  17. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jap J Cancer Res. 1998;89:1009–1013
  18. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, et al. Chemoprevention of azomethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994;54:5071–5074
  19. Rigas B, Tsioulias GJ, Allan C, Wali RK, Brasitus TA. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology. 1994;83:319–323
  20. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett. 1998;134:129–139
  21. Tung BY, Emond MJ, Haggit RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89–95
  22. Lindor KD, The Mayo PSC/UDCA Study Group . Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997;336:691–695
  23. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117:1288–1294
  24. Rubin PH, Freidman S, Harpaz N, Goldstein E, Weiser J, Schiller J, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of Gastroenterology. 1999;117:1295–1300
  25. Wolf JM, Rybicki L, Lashner BA. Ursodeoxycholic acid is not chemopreventive for colorectal cancer in ulcerative colitis patients with primary sclerosing cholangitis. Gastroenterology. 2001;120:A447; (abstr)
  26. Hill MJ, Melville DM, Lennard-Jones JE, Neale K, Ritchie JK. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet. 1987;2:185–186
  27. Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopcke W, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology. 1993;104:145–151
  28. Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS, Bruce WR. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett. 1988;38:315–320
  29. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer. 1977;39:2533–2539
  30. Ochsenkuhn T, Bayerdorffer E, Meining A, Schinkel M, Thiede C, Nussler V, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer. 1999;85:1664–1669
  31. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res. 1998;58:1684–1687
  32. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology. 1995;109:1835–1844
  33. Wali RK, Frawley BP, Hartmann S, Roy HK, Khare S, Scaglione BA, et al. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of colon carcinogenesis: potential roles of protein kinase C-α, -βII, and -ζ. Cancer Res. 1995;55:5257–5264
  34. Roy HK, Bissonnette M, Frawley BP, Wali RK, Niedziela SM, Earnest D, et al. Selective preservation of protein kinase C-ζ in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. FEBS Lett. 1995;336:143–145
  35. Khare S, Wali RR, Cerda SR, Nguyen LT, Hart JA, Stoiber D, et al. Ursodeoxycholic acid and a flourinated analogue of 1,25 (OH)2 vitamin D3 inhibit COX-2 overexpression in AOM-induced colonic carcinogenesis. Gastroenterology. 2000;188:A682

☆ Address requests for reprints to: Darrell S. Pardi, M.D., 200 First Street SW, Rochester, Minnesota 55905. e-mail: pardi.darrell@mayo.edu; fax: (507) 284-5486.

☆☆ Dr. Keith Lindor receives research funding from Axcan.

★ 0016-5085/03/$30.00

PII: S0016-5085(03)00070-2

Gastroenterology
Volume 124, Issue 4 , Pages 889-893 , April 2003

Article Tools

* Image Usage & Resolution